Nurix Therapeutics price target raised to $29 from $28 at RBC Capital

RBC Capital analyst Gregory Renza raised the firm’s price target on Nurix Therapeutics (NRIX) to $29 from $28 and keeps an Outperform rating on the shares. The firm notes that the pivotal study initiation and pipeline updates are positive developments that should pave the way for bex-deg’s initial late-line CLL opportunity while the company gears up to initiate its 2L+ confirmatory study in the first half of 2026. RBC continues to believe bex-deg has shown a competitive profile to date and with potential for more supportive data at ASH, and with meaningful optionality in exciting I&I collaborations that data from other companies’ programs could have positive read-throughs towards, it sees shares as undervalued given the large opportunities with their degrader platform.